MUC5AC and cancer: Ensituximab (Neo-102), a novel chimeric monoclonal antibody, binds to an aberrantly glycosylated cancer-associated MUC5AC variant and is able to activate the immune system to exert a cytotoxic T-lymphocyte response [47].